The prostate cancer condition center is a comprehensive resource for clinical news and expert insights on prostate cancer. Read more at OncLive.
April 26th 2024
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.
Ruben Olivares, MD, discusses focal therapy in the management of prostate cancer.
Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.
April 24th 2024
Mike Lattanzi, MD, discusses clinical trials that have evaluated the use of PARP inhibitor–based combination regimens in patients with mCRPC.
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
Jeffrey P. Townsend, PhD, on a novel approach to comprehending the evolutionary trajectory of prostate cancer through genetic profiling.
April 23rd 2024
Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.
The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.
April 19th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
April 18th 2024
Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.
April 17th 2024
Carmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.
Kara Maxwell, MD, PhD discusses a study of genetic testing results in metastatic prostate cancer.
April 16th 2024
Josep Maria Piulats Rodriguez, MD, discusses an analysis evaluating predictive biomarkers for treatment with talazoparib plus enzalutamide in mCRPC.
April 12th 2024
Phillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.
April 11th 2024
Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.
April 10th 2024
FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
April 5th 2024
Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.
April 4th 2024
Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.